DRKS00034406
Recruiting
Not Applicable
on-interventional, prospective, multicenter study to evaluate treatment satisfaction, treatment preference, quality of life, and tolerability under treatment with Briumvi® for relapsing forms of multiple sclerosis (RMS) with active disease in daily clinical practice - Briumvi® - Real World Experience Study (BRILL Study)
euraxpharm Pharmaceuticals, S.L.0 sites600 target enrollmentJune 11, 2024
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- G35
- Sponsor
- euraxpharm Pharmaceuticals, S.L.
- Enrollment
- 600
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Established clinical diagnosis of RMS with active disease.
- •\- Having been prescribed treatment with Briumvi® according to label and treatment is already initiated, with enrollment occurring no more than 90 days after the first dose.
- •Patient with newly prescribed Briumvi® in accordance with the label and about to start treatment with Briumvi® at Visit 1\.
- •\- Ability to understand the purpose and risks of the study and willing to provide signed and dated study\-specific ICF.
Exclusion Criteria
- •Patient cannot be regularly followed up for organizational or geographic reasons.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A prospective, randomized, multicenter, interventional study to evaluate the safety and effectiveness of the TactiCath® percutaneous ablation catheter for the treatment of symptomatic paroxysmal atrial fibrillation using contact force assisted irrigated radiofrequency ablatioatrial fibrillation10007521NL-OMON39773St. Jude Medical GVA Sàrl15
Completed
Not Applicable
Study regarding the safety of Gammanorm in autoimmune diseasesAutoimmune diseases which needs an immunoglobulin treatment - including dermatomyositis, polymyositis, inclusion body myositis, MMN, CIDPSkin and Connective Tissue DiseasesISRCTN32265704Octapharma France80
Completed
Not Applicable
An observational multicenter study comparing Tenecteplase assisted Percutaneous Coronary Intervention (PCI) versus primary PCI in Indian patients with ST elevation Myocardial InfarctioHealth Condition 1: null- Patients with acute STEMI who are to be treated with primary PCI/pharmacoinvasive therapy within 12 hours of symptoms onset will be included.CTRI/2011/08/001950STEMI India Charitable Trust200
Not yet recruiting
Phase 4
Multicentre, prospective, randomised clinical survey to evaluate early fusion rate after instrumented lumbar stabilization with either MectaLIF PEEK lumbar cage or MectaLIF TiPEEK lumbar cageDisorders that are treated with lumbar intervertebral body fusion, such as lumbar spondylolisthesisJPRN-UMIN000027744INCREASE Co., Ltd.240
Not yet recruiting
Not Applicable
Prospective, clinical, multicentric study to evaluate the influence of the length of the membranous urethra on stress urinary incontinence after robot-assisted radical prostatectomyC61Malignant neoplasm of prostateDRKS00024607Krankenhaus der Barmherzigen Brüder Wien500